Mount Sinai Hospital

In addition to dedicated treatment programs in hemophilia, sickle cell disease, and thrombophilia, our physicians provide care to children with anemia secondary to hemoglobinopathy, red cell membrane or enzyme disorders, aplastic anemia (including Fanconi’s anemia), thrombocytopenia (also known as ITP), neutropenia, polycythemia, and thrombocytosis.

Hematological conditions treated here include:

-Sickle cell disease
-Hemoglobinopathies
-Anemia
-Congenital and acquired thrombocytopenia including ITP
-Bleeding and clotting disorders

Our pediatric hematologists have been delivering state-of-the-art care to all patients with sickle cell disease for several decades. Basic research at Mount Sinai has included gene therapy for hemoglobinopathy, studies on cell interactions that lead to the excessive adhesion of red cells and enhancement of fetal hemoglobin to minimize the symptoms of sickle cell disease. The Sickle Cell Program here is a comprehensive program designed to provide holistic care. Patients have access to social workers, genetic counselors, cardiologists, pulmonologists, neurologists, and psychologists. Together with the experienced Pediatric Intensive Care Unit staff, the hospital treats the most life threatening complications such as stroke and acute chest syndrome. The blood bank provides accessibility to hemopheresis for emergencies.